Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions

Journal of Clinical Microbiology

Volumn 47, Issue 8, 2009, Pages 2604-2606

  Hosoya, Noriaki ^a   Su, Zhaohui ^b   Wilkin, Timothy ^c   Gulick, Roy M ^c   Flexner, Charles ^d   Hughes, Michael D ^b   Skolnik, Paul R ^e   Giguel, Françoise ^a   Greaves, Wayne L ^f   Coakley, Eoin ^g   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4;

ARTICLE; ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NONHUMAN; PRIORITY JOURNAL; TROFILE ASSAY; VIRION; VIROGENESIS; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TYPING;

HIV-1; HUMANS; PLASMA; RECEPTORS, VIRUS; SENSITIVITY AND SPECIFICITY; VIROLOGY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; REPLICATION COMPETENT VIRUSES;

EID: 68549109459     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00632-09     Document Type: Article

References (17)

1. Björndal, Å., H. Deng, M. Jansson, J. R. Fiore, C. Colognesi, A. Karlsson, J. Albert, G. Scarlatti, D. R. Littman, and E. M. Fenyo. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487.
2. Demeter, L. M., R. J. Bosch, R. W. Coombs, S. Fiscus, J. Bremer, V. A. Johnson, A. Erice, J. B. Jackson, S. A. Spector, K. M. Squires, M. A. Fischl, M. D. Hughes, and S. M. Hammer. 2002. Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J. Clin. Microbiol. 40:2089-2094.
3. Fatkenheuer, G., M. Nelson, A. Lazzarin, I. Konourina, A. I. Hoepelman, H. Lampiris, B. Hirschel, P. Tebas, F. Raffi, B. Trottier, N. Bellos, M. Saag, D. A. Cooper, M. Westby, M. Tawadrous, J. F. Sullivan, C. Ridgway, M. W. Dunne, S. Felstead, H. Mayer, and E. van der Ryst. 2008. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359:1442-1455.
4. Gulick, R. M., Z. Su, C. Flexner, M. D. Hughes, P. R. Skolnik, T. J. Wilkin, R. Gross, A. Krambrink, E. Coakley, W. L. Greaves, A. Zolopa, R. Reichman, C. Godfrey, M. Hirsch, D. R. Kuritzkes, et al. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients. J. Infect. Dis. 196:304-312.
5. Hollinger, F. B., J. W. Bremer, L. E. Myers, J. W. M. Gold, L. McQuay, and The NIH/NIAID/DAIDS/ACTG Virology Laboratories. 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J. Clin. Microbiol. 30:1787-1794.
6. Hosoya, N., Z. Su, T. Wilkin, R. M. Gulick, C. Flexner, M. Hughes, P. R. Skolnik, W. L. Greaves, E. Coakley, and D. R. Kuritzkes. 2007. 14th Conf. Retrovir. Opportunistic Infect., abstr. 181b.
7. Japour, A. J., S. A. Fiscus, J.-M. Arduino, D. L. Mayers, P. S. Reichelderfer, and D. R. Kuritzkes. 1994. Standardized microtiter assay for the determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J. Clin. Microbiol. 32:2291-2294.
8. Japour, A. J., S. Welles, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, C. S. Crumpacker, and D. R. Kuritzkes. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
9. Koot, M., A. H. V. Vos, R. P. M. Keet, R. E. Y. de Goede, M. W. Dercksen, F. G. Terpstra, R. A. Coutinho, F. Miedema, and M. Tersmette. 1992. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6:49-54.
10. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
11. Lu, J., P. Sista, F. Giguel, M. Greenberg, and D. R. Kuritzkes. 2004. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78:4628-4637.
12. Reeves, J., D. Han, T. Wilkin, T. Wrin, D. Kuritzkes, C. Petropoulos, J. Whitcomb, N. Parkin, R. Gulick, and E. Coakley. 2008. An enhanced version of the Trofile HIV co-receptor tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples, abstr. 869. Abstr. 15th Conf. Retrovir. Opportunistic Infect.
13. Schuitemaker, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E. Y. de Goede, R. P. van Steenwijk, J. M. A. Lange, J. K. M. E. Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66:1354-1360.
14. Simmons, G., D. Wilkinson, J. D. Reeves, M. T. Dittmar, S. Beddows, J. Weber, G. Carnegie, U. Desselberger, P. W. Gray, R. A. Weiss, and P. R. Clapham. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360.
15. Whitcomb, J. M., W. Huang, S. Fransen, K. Limoli, J. Toma, T. Wrin, C. Chappey, L. D. B. Kiss, E. E. Paxinos, and C. J. Petropoulos. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
16. Wilkin, T. J., Z. Su, D. R. Kuritzkes, M. Hughes, C. Flexner, R. Gross, E. Coakley, W. Greaves, C. Godfrey, P. R. Skolnik, J. Timpone, B. Rodriguez, R. M. Gulick, et al. 2007. Chemokine coreceptor tropism among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor. Clin. Infect. Dis. 44:591-595.
17. Zhang, L., T. He, Y. Huang, Z. Chen, Y. Guo, S. Wu, K. J. Kunstman, R. C. Brown, J. P. Phair, A. U. Neumann, D. D. Ho, and S. M. Wolinsky. 1998. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J. Virol. 72:9307-9312.